Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Covalent inhibitors: an opportunity for rational target selectivity
Roman Lagoutte, Rémi Patouret, Nicolas Winssinger
Current Opinion in Chemical Biology (2017) Vol. 39, pp. 54-63
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Matthias Gehringer, Stefan Laufer
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 12, pp. 5673-5724
Closed Access | Times Cited: 581
Advances in covalent drug discovery
Lydia Boike, Nathaniel J. Henning, Daniel K. Nomura
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 12, pp. 881-898
Open Access | Times Cited: 475
Advances in covalent kinase inhibitors
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, et al.
Chemical Society Reviews (2020) Vol. 49, Iss. 9, pp. 2617-2687
Closed Access | Times Cited: 256
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Tinghu Zhang, John M. Hatcher, Mingxing Teng, et al.
Cell chemical biology (2019) Vol. 26, Iss. 11, pp. 1486-1500
Open Access | Times Cited: 148
Fragment-based covalent ligand discovery
Wenchao Lu, Milka Kostić, Tinghu Zhang, et al.
RSC Chemical Biology (2021) Vol. 2, Iss. 2, pp. 354-367
Open Access | Times Cited: 107
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials
Timothy Panknin, Carol Howe, Meg Hauer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4476-4476
Open Access | Times Cited: 49
The Symbiotic Relationship Between Drug Discovery and Organic Chemistry
Oleksandr O. Grygorenko, Dmitriy M. Volochnyuk, Sergey V. Ryabukhin, et al.
Chemistry - A European Journal (2019) Vol. 26, Iss. 6, pp. 1196-1237
Closed Access | Times Cited: 141
Comparative Evaluation of Covalent Docking Tools
Andrea Scarpino, György G. Ferenczy, György M. Keserü
Journal of Chemical Information and Modeling (2018) Vol. 58, Iss. 7, pp. 1441-1458
Closed Access | Times Cited: 128
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro
Mubarak A. Alamri, Muhammad Tahir ul Qamar, Muhammad Usman Mirza, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 39, Iss. 13, pp. 4936-4948
Open Access | Times Cited: 119
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
Péter Ábrányi‐Balogh, László Petri, Tı́mea Imre, et al.
European Journal of Medicinal Chemistry (2018) Vol. 160, pp. 94-107
Closed Access | Times Cited: 103
10 Years Into the Resurgence of Covalent Drugs
Elena De Vita
Future Medicinal Chemistry (2020) Vol. 13, Iss. 2, pp. 193-210
Open Access | Times Cited: 100
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Hannah Kiely‐Collins, Georg E. Winter, Gonçalo J. L. Bernardes
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 952-968
Open Access | Times Cited: 91
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
S. Ray, Andrew S. Murkin
Biochemistry (2019) Vol. 58, Iss. 52, pp. 5234-5244
Closed Access | Times Cited: 85
Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking
Xiaobo Wan, Tangpo Yang, Adolfo Cuesta, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 11, pp. 4960-4964
Open Access | Times Cited: 81
A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations
Elma Mons, Sander Roet, Robbert Q. Kim, et al.
Current Protocols (2022) Vol. 2, Iss. 6
Open Access | Times Cited: 69
Navigating the Pauson–Khand Reaction in Total Syntheses of Complex Natural Products
Zhen Yang
Accounts of Chemical Research (2021) Vol. 54, Iss. 3, pp. 556-568
Closed Access | Times Cited: 61
Electrophilic warheads in covalent drug discovery: an overview
Nikolett Péczka, Zoltán Orgován, Péter Ábrányi‐Balogh, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 4, pp. 413-422
Closed Access | Times Cited: 54
Divergent Total Syntheses of (−)-Crinipellins Facilitated by a HAT-Initiated Dowd–Beckwith Rearrangement
Yifan Zhao, Jialei Hu, Ruyi Chen, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 6, pp. 2495-2500
Closed Access | Times Cited: 53
From quantum‐derived principles underlying cysteine reactivity to combating the COVID‐19 pandemic
Karine Mazmanian, Ting Chen, Karen Sargsyan, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 51
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
Xiang Zhai, Richard A. Ward, P. Doig, et al.
Biochemistry (2020) Vol. 59, Iss. 14, pp. 1428-1441
Closed Access | Times Cited: 63
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 20
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103557-103557
Closed Access | Times Cited: 19
Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues
Yuanyuan Zhao, Duan Kang, Youlong Fan, et al.
Communications Chemistry (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 8
N‐Cyanopiperazines as Specific Covalent Inhibitors of the Deubiquitinating Enzyme UCHL1
Mirko Schmidt, Christian Grethe, Sarah Recknagel, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 12
Open Access | Times Cited: 7
Friedel–Crafts reactions for biomolecular chemistry
Jun Ohata
Organic & Biomolecular Chemistry (2024) Vol. 22, Iss. 18, pp. 3544-3558
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top